Shenzhen Yuanxing Gene Technology

Shenzhen Yuanxing Gene Technology is a prominent Chinese biotechnology company specializing in the development and large-scale manufacturing of gene therapy products and viral vectors. Founded in 2001, the company has established itself as a key player in the global gene therapy landscape, serving as the industrialization base for Gendicine, the world's first approved gene therapy. Yuanxing operates a sophisticated platform for the production of adenovirus, AAV, and lentivirus vectors, offering comprehensive CDMO services to international partners. In 2021, the company gained further international recognition by entering into a major agreement with the Russian Direct Investment Fund to manufacture over 60 million doses of the Sputnik V COVID-19 vaccine. Their facilities are designed to meet international GMP standards, supporting both their internal pipeline of oncolytic viruses and the needs of external biopharmaceutical clients.